Phaseline

Targets › F2

F2 (Prothrombin): drug programs, companies and trials

19 programs from 18 companies in 26 trials: 13 Phase 4, 6 Phase 2, 4 Phase 3, 3 Phase 1; Cardiovascular, Hematology, Other; next expected readout Dec 2026.

Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing. Activates coagulation factor XI (F11); activation is promoted by the contact with negatively charged surfaces. (UniProt, P00734)

Open in Phaseline: the race on F2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Medical University of ViennaArgatroban
Thrombin inhibitor
F2Phase 4Respiratory InsufficiencyJan 2027
Herlev and Gentofte HospitalDabigatran Etexilate
Thrombin inhibitor
F2Phase 4Deep Vein Thrombosis; Atrial FibrillationMar 2027
Population Health Research InstituteDabigatran
Thrombin inhibitor
F2Phase 4Stroke; Bleeding Post Cardiac SurgeryJun 2027
Imperial College LondonDabigatran Etexilate
Thrombin inhibitor
F2Phase 4Venous ThromboembolismJun 2027
The University of Hong KongDabigatran etexilate
Thrombin inhibitor
F2Phase 4Atrial FibrillationSep 2027
McGill University Health Centre/Research Institute of the McGill University Health CentreDabigatran
Thrombin inhibitor
F2Phase 4Staphylococcus Aureus EndocarditisJan 2030
Peking University First HospitalBivalirudin
Thrombin inhibitor
F2Phase 4Coronary Microvascular Dysfunction–
Medical University of GdanskDabigatran Etexilate
Thrombin inhibitor
F2Phase 4Atrial Fibrillation–
Children's Hospital Los AngelesFeiba
Activated prothrombin complex concentrate (aPCC) - contains vitamin K-dependent clotting f
F2, F7, F10Phase 4Hemophilia A With Inhibitor–
CSL BehringProthrombin Complex Concentrate (BE1116)
Coagulation factor VII exogenous protein; Vitamin K-dependent protein S exogenous protein; Vitamin K-dependent protein C exogenous protein
F7, PROS1, PROC, F9, F2Phase 3Complex Cardiovascular Surgery With Cardiopulmonary Bypass; Cardiac Valve Disease; Hemophilia; Liver CirrhosisApr 2027
Icahn School of Medicine at Mount SinaiDabigatran
Thrombin inhibitor
F2Phase 3Atrial Fibrillation–
Icahn School of Medicine at Mount SinaiOral Anticoagulant (OAC) - Vitamin K Antagonist (VKA) or Direct Oral Anticoagula
Vitamin K antagonist or factor Xa/IIa inhibitor anticoagulation
F2, F7, F9, F10Phase 3Atrial Fibrillation–
New York Medical CollegeDefibrotide
Adenosine A2 receptor agonist; Plasminogen activator; Adenosine A1 receptor agonist
ADORA2B, ADORA2A, PLG, ADORA1, F2Phase 2Sickle Cell Disease; Sinusoidal Obstruction SyndromeDec 2026
Zhujiang HospitalNafamostat Mesilate
Serine protease inhibitor; anticoagulant
F2, F2R, PLAUPhase 2Continuous Renal Replacement Therapy (CRRT)Mar 2027
Stanford UniversityBivalirudin
Thrombin inhibitor
F2Phase 2Heart FailureSep 2027
Northwell HealthFEIBA
Factor VIII inhibitor bypass activity - prothrombin complex concentrate containing factors
F2, F7, F9, F10Phase 2Cardiac DiseaseNov 2028
Sydney Local Health DistrictBivalirudin
Thrombin inhibitor
F2Phase 2Extracorporeal Membrane Oxygenation Complication–
BayerBAY3389934
Factor IIa (thrombin) and Factor Xa inhibitor
F2, F10Phase 1Sepsis; Drug-drug InteractionDec 2026
Shaanxi Micot Pharmaceutical TechnologyMT1011
Factor IIa and Factor Xa inhibitor reversal agent
F2, F10Phase 1Used in Patients Receiving Anticoagulant Therapy (e.g., Rivaroxaban or Apixaban, Inhibitors of Coagulation Factor Xa) Who Require Reversal of Anticoagulation–

Conditions

Atrial Fibrillation (5) Staphylococcus Aureus Endocarditis (1) Deep Vein Thrombosis (1) Heart Failure (1) Venous Thromboembolism (1) Sickle Cell Disease (1) Sinusoidal Obstruction Syndrome (1) Stroke (1) Bleeding Post Cardiac Surgery (1) Sepsis (1) Drug-drug Interaction (1) Respiratory Insufficiency (1)

Modalities

small molecule (17), protein or peptide (2)

Companies

Icahn School of Medicine at Mount Sinai (2) McGill University Health Centre/Research Institute of the McGill University Health Centre (1) Herlev and Gentofte Hospital (1) Stanford University (1) Imperial College London (1) New York Medical College (1) Population Health Research Institute (1) Medical University of Gdansk (1) Bayer (1) Medical University of Vienna (1) Northwell Health (1) The University of Hong Kong (1) Shaanxi Micot Pharmaceutical Technology (1) Sydney Local Health District (1) Peking University First Hospital (1) CSL Behring (1) Children's Hospital Los Angeles (1) Zhujiang Hospital (1)

Related targets

F10 (5) F7 (4) F9 (3) ADORA2B (1) ADORA2A (1) PLG (1) ADORA1 (1) PROS1 (1) PROC (1) F2R (1) PLAU (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.